NCT06710158View on ClinicalTrials.gov

Study of SC-102 in Patients With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

December 5, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2027

Conditions
Advanced Solid Cancers
Interventions
DRUG

SC-102

SC-102 is a peptide drug conjugate (PDC) consisting an EphA2-targeting peptide, a tubulin inhibitor, and a protease-hydrolyzable linker.

Trial Locations (1)

Unknown

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Tianjin ConjuStar Biologics Co., Ltd.

INDUSTRY